research BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
Search
forLearn
0 / 0 results — no results
Research
5 / 319 resultsresearch Cutaneous Manifestations of Dabrafenib: A Selective Inhibitor of Mutant BRAF in Patients with Metastatic Melanoma
Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
research Inhibition of Mitochondrial Respiration Prevents BRAF-Mutant Melanoma Brain Metastasis
Stopping mitochondrial respiration can prevent brain cancer spread in skin cancer patients, and plant compound β-sitosterol could help achieve this.
research The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: The Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
research Wound Healing With Topical BRAF Inhibitor Therapy in a Diabetic Model Suggests Tissue Regenerative Effects
A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.
Community Join
1 / 1 resultscommunity Huge Group Buy is Now Live with New and Existing Treatments
A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.